Ambroxol Sustained Release 75 mg [Design Issues]

posted by DavidManteigas – Portugal, 2016-11-02 11:51 (3022 d 12:12 ago) – Posting: # 16764
Views: 3,062

Hi Maggie,

Which guideline are you refering? EMA or FDA? Didn't find any product-specific guideline on ambroxol bioequivalence...

If you're refering to a more general guidance, FDA guideline for BE studies with pharmacokinetic endpoints states de following (section IV, D, 3):

For modified release products, we recommend the following studies: (1) a single-dose, fasting study comparing the highest strength of the test with the RLD, and (2) a single-dose fed BE study comparing the highest strength of the test with the RLD product. Because single-dose studies are considered more sensitive in addressing the primary question of BE (e.g., release of the drug substance from the drug product into the systemic circulation), multiple-dose studies are generally not recommended

Complete thread:

UA Flag
Activity
 Admin contact
23,379 posts in 4,913 threads, 1,661 registered users;
154 visitors (0 registered, 154 guests [including 23 identified bots]).
Forum time: 00:04 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5